The European Medicines Agency (EMA) issued a positive opinion to recommend conditional marketing authorization (CMA) for the company's single-dose COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older.

If granted a CMA by the European Commission, the J&J single-shot COVID-19 vaccine will be available in the European Union. Studies of the vaccine have demonstrated protection against COVID-19-related hospitalization and death in broad geographic regions, including those with emerging variants.

Moderna doses 1st patients in COVID-19 vaccine booster trial
Moderna has dosed the first patients in its study of modified COVID-19 vaccines, designed to address the potential need for vaccine booster candidates.

Can a single dose of a vaccine designed as 2 doses be effective?
Researchers suggested that two doses of a COVID-19 vaccine are more protective than a single dose, even if the interdose period is longer than recommended....

J&J reports positive preclinical results for COVID-19 vaccine
Johnson & Johnson reported that its lead COVID-19 vaccine candidate protected against SARS-CoV-2 in preclinical studies.

J&J to start clinical trial for COVID-19 vaccine in July
Johnson & Johnson is accelerating its investigational SARS-CoV-2 vaccine candidate, Ad26.COV2-S, recombinant, with the initiation of a phase I/IIA...